RCT | Efficacy of a targeted-release formulation of budesonide for treating primary immunoglobulin A nephropathy.

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy – Kidney International

Commentary: Oral Steroid Safely Treats IgA Nephropathy: Trial Published – Medscape (free registration required)

Commentary on Twitter (thread – click for more)

https://twitter.com/hswapnil/status/1582685958881021952